Craig Wegner
Head
Emerging Innovations Unit, Scientific Partnering
AstraZeneca
Lithuania
Biography
He joined AstraZeneca in 2012 and currently champions an internal team responsible for the generation, prioritisation, and validation of repositioning ideas for small and large molecule compounds. Craig manages AstraZeneca’s partnership with the NIH/NCATS Discovering New Therapeutic Uses for Existing Molecules programme and Taiwan’s National Research Program for Biopharmaceuticals (NRPB) open innovation programme, among other alliances. He is also the co-creator and lead of AstraZeneca’s expanding Open Innovation platform, which partners the company’s assets and know-how with the disease insight and expertise of academic physician- and basic-scientists to advance pioneering research and therapies collaboratively for the benefit of patients.
Research Interest
business development
